Brief: Apotex First To Receive Health Canada Approval For Sevmia™, A Generic Semaglutide For Chronic Weight Management
BRIEF-Apotex First To Receive Health Canada Approval For Sevmia™, A Generic Semaglutide For Chronic Weight Management June 30 (Reuters) - Apotex Health Corp APTX.TO:
APOTEX FIRST TO RECEIVE HEALTH CANADA APPROVAL FOR SEVMIA™, A GENERIC SEMAGLUTIDE FOR CHRONIC WEIGHT MANAGEMENT
Source text: ID:nPnb11TPSa
Further company coverage: APTX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apotex Health
See all newsBrief: Apotex Health Corp. Announces Closing Of $1,250 Million Inaugural Senior Unsecured Notes Offering
Brief: Redhill Divests Talicia To Apotex For $18 Million Cash Upfront Plus Milestones
Brief: Apotex Announces First Quarter 2027 Results
Press Digest: Canada - July 29
Canada Research Roundup: Apotex Health, Manulife Financial, Sun Life Financial